MYSM1 is a chromatin-binding histone deubiquitinase. MYSM1 mutations in humans result in lymphopenia whereas loss of Mysm1 in mice causes severe hematopoietic abnormalities, including an early arrest in B cell development. However, it remains unknown whether MYSM1 is required at later checkpoints in B cell development or for B cell-mediated immune responses. We analyzed conditional mouse models Mysm1 Tg.CD21-cre mice showing no alterations in B cell numbers and largely normal responses to stimulation. MYSM1, therefore, has an essential role in B cell lineage specification but is dispensable at later stages of development. Importantly, MYSM1 activity at the prepro-B cell stage of development is important for the normal programming of B cell responses to stimulation once they complete their maturation process
Tg.CD21-cre mice showing no alterations in B cell numbers and largely normal responses to stimulation. MYSM1, therefore, has an essential role in B cell lineage specification but is dispensable at later stages of development.
Introduction
The 50 years since the discovery of the B cell lineage are marked by many major advances in the understanding of the molecular mechanisms regulating B cell development and effector functions [1] . These include the characterization of the mechanisms generating Ab diversity and the many developmental checkpoints involved in B cell development and in its subsequent differentiation to plasma cells or memory B cells during the adaptive immune response [2, 3] . This knowledge resulted in improved management of human diseases affecting B cell functions, including primary immunodeficiencies [4] , autoimmune disorders, and B cell leukemias and lymphomas [5] .
B cells develop in the bone marrow from CLPs through prepro-B, pro-B, pre-B, and immature B cell stages, which involves progressive activation of B cell transcriptional programs through sequential induction of the B cell lineage-specific transcription factors. These transcription factors include E12 and E47 helix-loop-helix proteins encoded by the E2A locus, early B cell factor EBF1, paired-domain transcriptional regulator PAX5, as well as IKAROS, BCL11A, FOXO1, IRF4, and IRF8 [6, 7] . A distinct transcriptional network is involved in the regulation of B cell activation during the adaptive immune response, including the germinal center reaction and subsequent B cell differentiation into plasma cells or memory B cells. Initiation and maintenance of the germinal center reaction requires transcription factors BCL6, PAX5, MEF2B, IRF8, and PU.1 [3, 5] , whereas plasma cell differentiation involves an antagonistic group of transcriptional regulators BLIMP1, IRF4, and XBP1 [2] . All these transcription factors work in concert with chromatin-modifying enzymes, including polycomb group complexes PRC2 and PRC1, histone acetylases MOZ and p300, and others [8] [9] [10] . Disruption in the activity of these transcriptional regulators can lead to defects in B cell development and humoral immunity, as well as B cell leukemia and lymphoma [5, 8] .
MYSM1 is a chromatin-interacting protein with DUB catalytic activity, previously shown to regulate gene expression through deubiquitination of histone H2A K119 [11, 12] . Recent studies show that MYSM1 has an essential role in multiple checkpoints in hematopoiesis and leukocyte differentiation. MYSM1 is required for maintenance of HSC functions [13, 14] , enforcing HSC quiescence, and promoting survival of multipotent progenitors. It is also required for NK cell maturation [15] , and for the survival and development of double-negative T cell precursors within the thymus [16] . The essential role of MYSM1 in hematopoiesis and leukocyte differentiation is further demonstrated in rare human patients homozygous for MYSM1 E390* or H656R mutations, who have reduced leukocyte numbers in circulation, as well as other features of bone marrow failure [17, 18] .
Severe depletion of B cells is one of the striking features of Mysm1 2/2 mice [13, 19] , and reduced B cell numbers are also observed in human patients with MYSM1 deficiency [17, 18] . However, the complex hematopoietic features of the Mysm1
phenotype that affect HSCs, multipotent progenitors, and CLPs, pose a significant challenge to the understanding of MYSM1 functions specifically within the B cell lineage. The Mysm1 transcript is expressed throughout B cell lineage differentiation, as well as in mature B cells in secondary lymphoid organs [19] . Mechanistically, MYSM1 was shown to regulate Ebf1-locus expression, to promote H2AK119-deubiquitination of Ebf1-promoter, and to affect local recruitment of other transcriptional regulators, such as PU.1, E2A, and SWI/SNF-complex components [19] . Another study in Mysm1 2/2 mice reported MYSM1
as a repressor of plasma cell differentiation; however, the almost complete loss of B cells in this model complicates the interpretation of this data [20] . MYSM1 also has a poorly understood role in the regulation of the p53 stress response in the hematopoietic system [16, 21, 22] , and loss of p53 in the Mysm1-knockout mouse can restore normal hematopoiesis and fully rescue B cell lineage development [21] . The relationship between impaired Ebf1 expression in Mysm1-deficient CLPs and prepro-B cells [19] and the apparent depletion of these cells through p53-driven mechanisms remains to be explored further. Interestingly, in a recent high-throughput screen, MYSM1 was shown to localize to sites of DNA breaks [23] , suggesting that, beyond its role in transcriptional regulation, it may be involved in DNA repair, raising questions about its possible involvement in immunoglobulin gene rearrangements, such as B cell class switching. Despite rapid advances in the understanding of MYSM1 functions in B cell lineage specification, as well as in other hematopoietic lineages, the roles of MYSM1 at later checkpoints of B cell development remain poorly understood and are addressed in our current work.
MATERIALS AND METHODS

Mouse lines
Conditional mouse line Mysm1 fl/fl , previously described [24] , was bred to 
Mouse immunization
Mice were immunized s.c. in both flanks with immunogen emulsion containing 100 ml of PBS, 100 ml of CFA (Thermo Fisher Scientific) and 15 mg of R-PE (ProZyme, Hayward, CA, USA), vortexed for 45 min before injection.
Flow cytometry
For immunophenotyping of mouse tissues, cell suspensions were subjected to red blood cell lysis in ACK (ammonium-chloride-potassium) buffer and stained with the 
B cell isolation
B cells were isolated with CD45R MicroBeads and the AutoMACS Pro Separator (Miltenyi Biotec, San Diego, CA, USA), according to the manufacturer's protocols. Subsequent sorting of distinct B cell subpopulations was performed on the FACSAria instrument (BD Biosciences).
In vitro B cell cultures
For in vitro stimulation, mouse splenocytes or AutoMACS-isolated B cells were plated in RPMI-1640 medium with 10% (v/v) FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 mg/ml streptomycin, and 100 U/ml penicillin (all from Wisent Bioproducts, Saint-Jean-Baptiste, QC, Canada), and 5 3 10 25 M b-mercaptoethanol (Calbiochem; EMD Millipore, Billerica, MA, USA). The cells were stimulated with LPS (1 mg/ml; EMD Millipore), or LPS (1 mg/ml) plus IFN-g (50 ng/ml; PeproTech, Rocky Hill, NJ, USA), or anti-CD40 (eBioscience, 2 mg/ml) plus IL-4 (5 ng/ml; PeproTech), with or without goat F(ab9) 2 anti-mouse IgM (10 mg/ml; SouthernBiotech). For the analysis of proliferation, the cells were preloaded with CFSE (eBioscience). For B cell differentiation, bone marrow cells were plated on OP9-feeders (a gift from Dr. Juan Carlos Zúñiga-Pflücker, Sunnybrook Health Sciences Centre, Toronto, ON, Canada), in IMDM (Thermo Fisher Scientific), with 10% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 mg/ml streptomycin, 100 U/ml penicillin (all from Wisent Bioproducts), 50 mM b-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA), 10 ng/ml Flt-3L, and 10 ng/ml IL-7 (PeproTech).
Immunofluorescence microscopy
Spleens were frozen in OCT (Sakura Finetek, Tokyo, Japan), sectioned at 5 mm using Leica CM3050 cryostat (Leica Microsystems, Wetzlar, Germany), fixed for 7 min in ice-cold acetone, and air-dried. Sections were rehydrated in TBS, followed by TBST (Sigma-Aldrich), and blocked for 30 min in TBST with 10% rabbit serum (Jackson ImmunoResearch Laboratories, West Grove, PA, USA), 10% mouse serum (Jackson ImmunoResearch Laboratories), 5% BSA (Sigma-Aldrich), and 2 mg/ml anti-mouse CD16/CD32 (clone 93; BioLegend). Fluorochrome-labeled Abs were applied for 60 min, including antimouse CD45R/B220-PE (clone RA3-6B2; BioLegend), TCRb-FITC (clone H57-597; Tonbo Biosciences), anti-metallophilic macrophages biotin (clone MOMA-1; Abcam, Cambridge, MA, USA) followed by streptavidin-eFlour450 (eBioscience). Slides were washed 3 times with TBST, once with TBS, and 3 times with PBS and were mounted with Gel/Mount (Biomeda, Foster City, CA, USA).The images were acquired on Zeiss LSM710 laser scanning confocal microscope (Carl Zeiss Microscopy, Thornwood, NY, USA), with PlanApochromat 320 NA 0.8 objective, and Zen 2011 software, pixel size 0.415 mm, 1024 3 1024 pixels.
ELISA
Naïve serum ELISAs used anti-mouse IgM II/41, IgG1 A85-3, IgG3 R2-38, and IgG2a R11-89 (BD Biosciences) capture Abs at 1 mg/ml and were developed with goat anti-mouse IgG(H + L)-HRP (SouthernBiotech), followed by SuperAquaBlue substrate (eBioscience). For Ag-specific Ab titers, plates were coated with R-PE (10 mg/ml; ProZyme), and developed with biotin goat antimouse IgM, IgG1, IgG2c, and IgG3 Abs (SouthernBiotech), followed by streptavidin-peroxidase (R&D Systems, Minneapolis, MN, USA) and SuperAquaBlue Substrate (eBioscience). Plates were imaged with an EnSpire 2300 multilabel reader (PerkinElmer, Waltham, MA, USA).
RNA isolation and quantitative RT-PCR
RNA extraction was performed using EZ-10 DNAaway RNA kit (Bio Basic, Amherst, NY, USA) according to manufacturer's protocol. cDNA was prepared using the Moloney murine leukemia virus reverse-transcription kit and quantitative PCRs run on a StepOnePlus instrument with PowerSYBR master mix (all from Thermo Fisher Scientific). Primers were purchased from Integrated DNA Technologies, and primer sequences were: Ebf1-Fw AACCTTCCTCAATGGCTCAG, Ebf1-Rv AGAAGATGCCAGAGGAGCTA, P a x 5 -F w G A C A G C A C T A C T C T G A C A T C T T C , P a x 5 -R v GTCAAGTTGGCTTTCATGTCATC. Primers for Mysm1 were previously published [22] .
Statistical analyses
Statistical analyses used Prism 4.0 (GraphPad Software, La Jolla, CA, USA), with the Student's t test for 2 data sets and ANOVA for multiple comparisons.
RESULTS AND DISCUSSION
Generation of B cell specific conditional knockout mouse models
To address the role of MYSM1 at different stages of B cell lineage maturation and in the B cell-mediated immune response, B cell-specific conditional knockout mouse models were generated by crossing Mysm1-floxed mouse line Mysm1 fl/fl to transgenic lines expressing Cre-recombinase under the control of different B cell lineage-specific promoters: Tg.mb1-Cre [27] , Tg.CD19-Cre [25] , and Tg.CD21-Cre [26] . The resulting (Fig. 1A) . As expected, the Mysm1 fl allele remained intact in the ear-clip tissues of the same mice, used as negative controls (Fig. 1A) . Furthermore, Mysm1-transcript levels were dramatically reduced in Mysm1 fl/fl Tg.mb1-cre B cells and were close to the limit of detection (Fig. 1B) Fig. 1A) .
To gain further insight into the B cell developmental defect of the Mysm1 fl/fl Tg.mb1-cre mouse line, the bone marrow of the mice was analyzed for the different lymphoid progenitor populations ( Fig. 2A-D [28] , and a significant reduction was observed in the numbers of fraction B and C pro-B cells but not in the fraction A prepro-B cells, consistent with our earlier findings ( Fig. 2C and D) . We also observed an increased level of cell apoptosis, as measured by annexin V staining, in pre-B cells and immature B cells of Mysm1 fl/fl Tg.mb1-cre mice ( Fig. 2E and F) . Impaired B cell viability was also seen in vitro with Mysm1 fl/fl Tg.mb1-cre bone marrow plated for 5 d on OP9 feeders in the presence of cytokines Flt-3L and IL-7 (Supplemental Fig. 1B-D) . Given the importance of IL-7 as a prosurvival signal for the B cell lineage, the expression of IL7Ra on Mysm1 fl/fl Tg.mb1-cre B cell progenitors was tested but was found to be largely normal (Supplemental Fig. 1E ). Interestingly, we observed consistent increases in p53 protein levels within Fig. 2A and B). The data were reproducible in experiments conducted with purified B cells ( Fig. 3B and C) , as well as when B cells were analyzed in total splenocyte cultures (Supplemental Fig. 2A and  B) . In contrast, the induction of these activation markers on experiments for each of the 3 mouse lines. *P , 0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001, NS, not significant using ANOVA with Bonferroni post hoc test. Fig. 5C ). However in naïve Mysm1 fl/fl Tg.mb1-cre mice, the overall pool of class-switched memory B cells was, nevertheless, reduced ( Fig. 5A and B) , which likely reflects the long-term effects of the impaired Mysm1 5D ), suggesting no major role of MYSM1 in the regulation of germinal center vs. memory B cell fate decisions. Levels of Ag-specific Abs in the serum of Mysm1 fl/fl Tg.mb1-cre mice were also analyzed; however, they were found to be normal for all the assessed isotypes at d 14 postimmunization (Fig. 5F ), indicating Tg.mb1-cre and control bone marrow and spleen, gated as described above. pro-B and pre-B cells in another report [29, 30] . Similarly, Ebf1
fl/fl
Tg.CD23-cre mice exhibit a reduction in mature B cells, including marginal zone cells [29, 30] and impaired B cell class switching and Ab production [29] , whereas Mysm1 fl/fl Tg.CD21-cre mice do not show significant phenotypic abnormalities. Overall, this suggests that, beyond its role in the induction of Ebf1 expression during B cell lineage priming [19] , MYSM1 has transcriptional targets other than Ebf1 at later stages of B cell lineage differentiation. Recent studies identified many genes marked by histone H2AK119-ubiquitination in mouse B cells and established the role of H2AK119-deubiquitinase USP16 in the regulation of B cell quiescence [31] . The Mysm1-conditional knockout mouse models established in our current work may lead to similar characterization of the effects of MYSM1 on Tg.mb1-cre mice at 24 h of stimulation with LPS. Bars represent means 6 SEM; data are from 4-5 mice per group. *P , 0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001, NS, not significant using ANOVA with Bonferroni post hoc test.
H2AK119-ubiquitination in B cells and to the identification of other B cell-specific genes regulated by MYSM1.
Our previous work indicates that B cell depletion and most other hematopoietic defects in the Mysm1 2/2 mouse model are mediated by p53 hyperactivation and can be restored to wildtype levels in Mysm1 2/2 p53 2/2 double-knockout mice [16, 21, 22] .
In this work, we observed increased p53 protein levels in B cell progenitors and in mature B cells of Mysm1 fl/fl Tg.mb1-cre mice, suggesting that p53-mediated mechanisms may underlie the increased apoptosis and depletion of Mysm1 fl/fl Tg.
mb1-cre B cell progenitors, as well as the defects in Mysm1
Tg.mb1-cre B cell survival and proliferation in response to stimulation. Further work will be needed to fully unravel the molecular mechanisms that underlie the relationship between p53 and these Mysm1 fl/fl Tg.mb1-cre phenotypes. Precise regulation of p53-stress response signaling is essential for normal B cell development, allowing B cells to maintain survival and proliferation while undergoing genomic rearrangements of their B cell receptor loci including V(D)J recombination, Ig class-switch recombination, and somatic hypermutation [32] . Transcriptional repressor BCL6 is known to antagonize p53 activity at the pre-B cell receptor checkpoint and during B cell class switching [32] switching. This is also consistent with the analysis that shows the presence of class-switched Abs in the plasma of human MYSM1-deficient patients. [17, 18] . The conclusion is interesting, given the known role of histone H2A ubiquitination in the resolution of DNA breaks during the Ig class-switching reaction. This is supported by the recent studies reporting defects in class-switch recombination and humoral immunity in knockout mouse lines for ubiquitin ligases RNF8 and RNF168, which are essential for the deposition of K63-polyubiquitin chains on histone H2A at DNA breaks [37] [38] [39] . Interestingly, in a recent high-throughput screen of DUB enzymes, MYSM1 was shown to localize to DNA breaks [23] , suggesting its possible role in the regulation of chromatin structure during DNA break repair. However, our study argues against the direct, nonredundant role of MYSM1 in repair and resolution of DNA breaks during the B cell classswitching reaction and highlights the need to search for other DUBs that oppose RNF8/RNF168 activity to regulate histone H2A ubiquitination during B cell class switching [11] . Possible candidates include BRCC36, USP3, and BAP1 [11, 40] . Regarding the role of MYSM1 in humoral immune response, future studies can use the Mysm1 fl/fl Tg.CD21-cre mouse model established in our work to address its role in Ab affinity maturation, which was not directly tested in our study.
In summary, our study demonstrates that, although MYSM1 is largely dispensable in mature B cells, its activity at the prepro-/ pro-B cell stages of development is required for the normal programming of B cell responses to Ag stimulation once they complete their maturation process. This provides further insights into epigenetic controls of B cell lineage differentiation and into the immunologic abnormalities in human MYSM1-deficiency syndrome.
